Background: Platinum-based drugs such as Cisplatin are commonly employed for cancer treatment. Despite an initial therapeutic response, Cisplatin treatment often results in the development of chemoresistance. To identify novel approaches to overcome Cisplatin resistance, we tested Cisplatin in combination with K þ channel modulators on colorectal cancer (CRC) cells.
Platinum-based drugs and, in particular, cis-diamminedichloridoplatinum (II), best known as Cisplatin, are employed for the treatment of a wide range of solid malignancies, including colorectal cancer (CRC). Cisplatin exerts anticancer effects by inducing the formation of platinum-DNA adducts (Huang et al, 1995) , which in turn trigger the apoptotic process (Wang and Lippard, 2005) . Cisplatin also produces 'non-genomic effects', affecting plasma membrane proteins, including ion channels and transporters, and cytoskeletal components. Such effects are often related to Cisplatin side effects, such as peripheral neuropathy (Carozzi et al, 2015) .
Despite a consistent rate of initial responses, Cisplatin treatment often results in the development of resistance, leading to therapeutic failure. Intense research has identified several mechanisms underlying Cisplatin resistance (Galluzzi et al, 2014) . Among them, reduced uptake of Cisplatin through the plasma membrane is one of the most critical 'pretarget' steps of resistance development. Cisplatin is taken up by both simple and facilitated diffusion (Yoshida et al, 1994; Ishida et al, 2002) . Relevant in the latter process are the copper (Cu) transporters CTR1 and CTR2, encoded by the SLC31A genes 1 and 2, respectively. Altered levels or mis-functionality of CTR1 and CTR2 are consistently associated with Cisplatin resistance (Katano et al, 2002; . Moreover, extrusion of the drug by two P-type ATPases, ATP7A and ATP7B is also operant. Altered expression and cellular localisation of such ATPases has been linked to the occurrence of Cisplatin resistance in ovarian cancer (Kalayda et al, 2008) . Plasma membrane transporters are not only involved in the transport of the drug but can also be affected by Cisplatin itself . For example, when apoptosis is triggered, an early persistent shrinkage (named apoptotic volume decrease) results as a consequence of efflux of K þ and the activation of an outwardly rectifying Cl À current. The latter has the electrophysiological and pharmacological characteristics of volume regulated anion channels (VRAC) (Lang and Hoffmann, 2012) . Recently, VRAC, and in particular the LRCC8A and LRCC8D molecular components, have been shown to influence Cisplatin uptake (Jentsch et al, 2016) . Not surprisingly, a reduction of anion currents through VRAC has been linked to Cisplatin chemoresistance Poulsen et al, 2010) . K þ channels are frequently dysregulated in cancer (Arcangeli et al, 2009; D'Amico et al, 2013) . In particular, K Ca 3.1 and K v 11.1 are upregulated during tumour progression (Lastraioli et al, 2004; Muratori et al, 2016) and contribute to malignancy, which includes chemoresistance (Pillozzi et al, 2011) . Interestingly, Cisplatin sensitivity is related to K þ channel expression and activity in several cancer cell lines Zhang et al, 2012; Leanza et al, 2014; Hui et al, 2015; Samuel et al, 2016) . For example, increased activity of intermediate-conductance K Ca 3.1 (KCNN4) calcium-activated K þ currents (I IK ) contributes to Cisplatin sensitivity in epidermoid cancer cells and I IK activation consistently potentiates Cisplatin-induced cytotoxicity. In contrast, expression of large-conductance K Ca 1.1 (KCNMA1, BK) calcium-activated channels is reduced in Cisplatin-resistant ovarian cells (Samuel et al, 2016) . In patients with ovarian cancer treated with Cisplatin-based adjuvant chemotherapy, decreased expression of K v 10.1 (KCNH1, Eag1) correlates with favourable prognosis and predicts Cisplatin sensitivity in ovarian cancer cells (Hui et al, 2015) . K v 11.1 (hERG1) channels have been found to be upregulated by Cisplatin in gastric cancer cells, and their silencing decreases the cytotoxic effects of the drug (Zhang et al, 2012) . Moreover, a clear correlation between K þ channel expression and Cisplatin sensitivity was shown in cancer cell lines of different histogenesis (Leanza et al, 2014) .
Here we investigated the role of K þ channels in Cisplatin resistance in CRC and tested the possibility of overcoming Cisplatin resistance with K þ channel-modulating agents.
MATERIALS AND METHODS
Chemicals and antibodies. Unless otherwise indicated, all chemicals, drugs and antibodies were from Sigma-Aldrich, Milan, Italy. For in vitro experiments Riluzole, SKA-31 and TRAM-34 were dissolved in DMSO, at a concentration of 5 mM, whereas for in vivo experiments Riluzole was dissolved in 5% Kolliphor in 0.9% NaCl. E4031 dihydrochloride, Cisplatin and Oxaliplatin were dissolved in bi-distilled water. All stock solutions were stored at -20 1C. The list of antibodies and the concentrations used for western blotting (WB) experiments are reported in Supplementary Methods.
Cell culture. All the CRC cell lines were cultured in RPMI-1640 medium (Euroclone; Milan, Italy), supplemented with 2% L-Glut, 10% foetal bovine serum (Euroclone) and 1% penicillin/streptomycin (complete medium). HCT-116 cells were obtained from the American Type Culture Collection ATCC (Manassas, VA, USA); HT-29 cells were kindly provided by Dr R Falcioni (Regina Elena Cancer Institute, Roma, Italy); HCT-8 and H630 were kindly provided by Dr E Mini (University of Florence, Florence, Italy).
Total RNA extraction, reverse transcription and RQ-PCR. RNA extraction, reverse transcription (RT) and RQ-PCR were as described in Pillozzi et al, 2007 . The primers relative to ATP7A, ATP7B, KCNA3, KCNH1, KCNH2, KCNMA1, KCNN3, KCNN4, SLC31A1, SLC31A2, LRCC8A and LRCC8D are shown in Supplementary Table S1 .
Silencing of HCT-116 cells. Silencing of HCT-116 cells was carried out as in Crociani et al, 2013 , using the following siRNAs:
(1) K V 11.1/KCNH2-siRNAs (44858 anti-Kv11.1 siRNA1 and 44762 anti-Kv11.1 siRNA3, Ambion; Austin TX, USA) (total 100 nM final concentration) and (2) K Ca 3.1/KCNN4-siRNAs (7801 anti-kcnn4 siRNA1 and 7803 anti-kcnn4 siRNA3, Ambion) (total 5 nM final concentration). As negative controls, cells were treated with Lipofectamine only.
Cell viability assay, IC 50 and Combination Index (CI) calculation. Cell viability was measured through the Trypan Blue exclusion test, following the procedure described in Pillozzi et al, 2016 . IC 50 and CI calculations are as in Pillozzi et al, 2011 . Cells were seeded at 1 Â 10 4 per well in 96-well plates (Costar Corning, Cambridge, MA, USA) in complete medium; Cisplatin and the other drugs were added at their final concentration after 24 h incubation and further incubated for different times.
Cell cycle analysis. Cell cycle distribution was assessed by flow cytometry after staining cells with propidium iodide (PI) as in Pillozzi et al, 2016 .
Annexin/PI assay. Apoptosis was determined using the Annexin V/PI test (Annexin-V FLUOS Staining Kit; Roche Diagnostics, Mannheim, Germany) as described in Pillozzi et al, 2011. According to this procedure, (i) viable cells are negative for both Annexin V and PI (Q3 quadrant gate in the dot plots); (ii) cells that are in the early phases of apoptosis are Annexin V positive and PI negative (Q4 quadrant gate in the dot plots); (iii) cells that are in the late phases of apoptosis are both Annexin V and PI positive (Q2 quadrant gate in the dot plots); and (iv) dead (necrotic) cells are Annexin V negative and PI positive (Q1 quadrant gate in the dot plots).
Patch-clamp experiments. Membrane currents were recorded at room temperature (25 1C) with the whole-cell configuration of the patch-clamp technique. K v 11.1 currents were elicited by a two-step protocol, conditioning the cell at 0 mV and testing the tail current at -120 mV (Gasparoli et al, 2015) . K Ca 3.1 currents were elicited by 200-ms voltage ramps from À 120 to þ 40 mV applied every 10 s, and the fold increase of slope conductance by drug was taken as an indication of channel activation (Sankaranarayanan et al, 2009 ). All the solutions are mentioned in Supplementary Table S2 . The effects of Riluzole, SKA-31 and Cisplatin were determined on maximal K v 11.1 tail currents. The effects of Cisplatin and TRAM-34 were determined on the maximal K Ca 3.1 activation induced by Riluzole and SKA-31. Drugs were applied at the concentrations indicated in the figure legends for 2 min before recording their effects. Resting potential (V REST ) values were measured in I ¼ 0 mode, in the presence of the extracellular solution No. 1 (see Supplementary Table S2 ).
Immunofluorescence.
Immunofluorescence was performed applying the procedures detailed in Lastraioli et al, 2015, using the antibodies reported in Supplementary Methods.
Protein extraction and WB. Protein extraction and WBs relative to cell lines and tumour masses were performed as described in Crociani et al, 2013 , using the antibodies reported in Supplementary Methods.
Cisplatin uptake measurement. HCT-116 cells were incubated in complete medium containing the different compounds as reported in the legend of Figure 4 for 3 or 24 h. For incubation in high extracellular K þ , NaCl in the RPMI medium was substituted in part (to obtain 40 mM KCl) or totally (to obtain 108 mM KCl) with KCl. At the end of the uptake period, cells were quickly washed three times with ice-cold PBS, collected, gently spun down (1.000 g for 5 min at 4 1C), and the pellet suspended in 1 ml ice-cold PBS. Part (50 ml) of this suspension was taken for protein concentration determination and part (50 ml) for cell viability assay. The remaining 900 ml were spun down at 400 g for 5 min and processed for ICP-AES analysis as described in Marzo et al, 2015. In vivo experiments. Experiments were performed at the Animal House of the University of Florence (CESAL). Mice were housed in filter-top cages with a 12 h dark-light cycle and had unlimited access to food and water. Procedures were conducted according to the laws for experiments on live animals (Directive 2010/63/EU) and approved by the Italian Ministry of Health (1279/2015-PR). All the procedures are detailed in Supplementary Methods.
Statistical analysis. Unless otherwise indicated, data are given as mean values ± s.e.m., with n indicating the number of independent experiments. Statistical comparisons were performed with Origi-nPro 2015 (Origin Lab, Northampton, MA, USA). The normality of data distribution was checked with Kolmogorov-Smirnov test. In case of unequal variances, the Welch correction was applied. For comparisons between two groups, we used Student's t-test. For multiple comparisons, one-way ANOVA followed by Bonferroni's post hoc test was performed to derive P-values. The individual P-values are reported in the Figures.
RESULTS

Effects of Cisplatin on different CRC cell lines: identification of
Cisplatin-resistant and -sensitive cell lines. We investigated the response of four CRC cell lines to Cisplatin treatment by measuring the cell viability by Trypan Blue exclusion test. The inhibiting concentration 50 (IC 50 ) values determined after 24 h of treatment ( Figure 1A) show that HCT-116 cells are the most resistant and HCT-8 the most sensitive (see also Table 1A and Supplemetary Table S3 ). Cisplatin, added at its IC 50 value to the two cell lines, triggered apoptosis (with a higher percentage of cells in late apoptosis in HCT-8 cells than in HCT-116 cells ( Figure 1B , Table 1A ) and increased the percentage of G0/G1 cells in both cell types (Table 1A and Supplementary Figure S1 ) after 24 h of treatment. Cisplatin blocked cell proliferation in HCT-8 at 1 mM ( Figure 1C , left panel), while in HCT-116 at 20 mM ( Figure 1C , right panel). In summary, HCT-116 is a Cisplatin-resistant line, while HCT-8 is Cisplatin sensitive.
We next determined the expression of different K þ channel genes (Spitzner et al, 2007; D'Amico et al, 2013; Huang and Jan, 2014) and Cisplatin transporter systems (Owatari et al, 2007; Pedersen et al, 2015; Barresi et al, 2016; Jentsch et al, 2016) in the two CRC cell lines, focussing on those already reported to be expressed in CRC cells and primary samples. RQ-PCR data are shown in Figure 1D . K v 11.1 (KCNH2, hERG1) was expressed at higher levels in HCT-116 than HCT-8 cells. The K Ca 3.1 (KCNN4) transcript was also highly expressed in HCT-116 cells and much less so in HCT-8 cells. All other tested K þ channel transcripts were negligible in both cell lines. The copper transporter CTR1 (SLC31A1) was highly expressed in both cell lines; the two P-type ATPases, ATP7A (ATP7A) and ATP7B (ATP7B) displayed a higher amount in HCT-8 cells; the LRRC8A/D (LRCC8A and LRCC8D) components of VRAC were only found in HCT-116 cells.
The higher expression of both K v 11.1 (KCNH2, hERG1) and K Ca 3.1 (KCNN4) in HCT-116 compared with HCT-8 cells was confirmed by WB ( Figure 1E ), immunofluorescence ( Figure 1F ) and patch-clamp experiments. Larger K v 11.1 currents were previously reported in HCT-116 than in HCT-8 cells (Crociani et al, 2013, and Supplementary Figure S2 ). A calcium-activated K þ current with characteristics of K Ca 3.1 was detected only in HCT-116 cells but only after the channel was activated by Riluzole or SKA-31 ( Figure 2A ). HCT-116 cells showed a significantly hyperpolarised V REST ( À 38.5 ± 2.9 mV, n ¼ 11) compared with HCT-8 cells ( À 13.1 ± 2.5 mV, n ¼ 12, po0.01), consistent with their higher expression of K þ channels.
Modulators of K Ca 3.1 and K v 11.1 channels affect viability, apoptosis and cell cycle phases of CRC cells. Next, we tested on our cell lines the effects of activators or inhibitors of K Ca 3.1 and inhibitors of K v 11.1. Riluzole was used as a broad modulator of ion channels, as it activates K Ca currents (both intermediate-conductance K Ca 3.1 and small-conductance K Ca 2.1, K Ca 2.1 and K Ca 2.3 currents) and inhibits K v 11.1 (Sankaranarayanan et al, 2009 ), voltage-gated sodium (Wang et al, 2008) and voltage-gated calcium channels (Stefani et al, 1997) . SKA-31 is a specific K Ca 3.1 activator (Sankaranarayanan et al, 2009 ) and TRAM-34 a specific K Ca 3.1 inhibitor (Wulff et al, 2000) . E4031 inhibits K v 11.1 (Sanguinetti and Jurkiewicz (1990) ). We first tested these compounds on HCT-116 cells. Both Riluzole and SKA-31 increased the K Ca 3.1 current (reversal potential at À 80 mV; inhibition by TRAM-34) 2.11±0.46 (n ¼ 9) and 4.36±1.67 (n ¼ 10) fold, respectively (Figures 2A and C) and induced cell hyperpolarisation (Figure 2A ). Riluzole also inhibited K v 11.1 currents (by 23 and 44%, with 10 and 45 mM, respectively) ( Figures 2B and C) , in keeping with previous reports (Sankaranarayanan et al, 2009 ). SKA-31 had no effect on K v 11.1 currents ( Figures 2B and C) .
In current-clamp experiments, both Riluzole and SKA-31 strongly hyperpolarised V REST (Figure 2E , right panel). In contrast, TRAM-34 ( Figure 2D ) and E4031 ( Figure 2E ) depolarised V REST . Cisplatin did not significantly affect K Ca 3.1 currents either in control conditions or after SKA-31 stimulation (Figures 2B and F) and slightly inhibited K v 11.1 (Figures 2B and G) . Cisplatin addition rapidly and reversibly depolarised V REST ( Figure 2H ).
Next, we tested the effects of Riluzole, SKA-31, E4031 and TRAM-34 on cell viability, apoptosis and cell cycle phases of HCT-116 and HCT-8 cells. All these compounds reduced cell viability, but differently from Cisplatin, their IC 50 values were generally lower in HCT-116 than in HCT-8 cells, except for TRAM-34 (Table 1A and Supplementary Table S3 ). All the K þ channel modulators triggered apoptosis in HCT-116 cells, and the effect was smaller in HCT-8 cells (Table 1A) . They also increased the percentage of cells in G0/G1 phase, in both cell lines, with the 
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Ct value Score of expression (a.u.) exception of Riluzole, which caused a strong G2/M block in HCT-8 cells (Table 1A) , as reported by Khan et al (2011) . All drugs reduced HCT-116 cell proliferation when added at time zero at their specific IC 50 values ( Figure 3A ). Less evident effects were observed in HCT-8 cells (Supplementary Figure S3 ).
Score
K Ca 3.1 activation and K v 11.1 block have a synergistic activity with the pro-apoptotic effects of Cisplatin. We tested the different K þ channels modulators in combination with Cisplatin in HCT-116 and HCT-8 cells and measured the CI to assess synergistic, antagonistic or additive effects of the different combinations (Pillozzi et al, 2011) . Riluzole, SKA-31 and E4031 synergised with Cisplatin in decreasing viability of HCT-116 cells after a 24 h incubation, whereas TRAM-34 was antagonistic (Table 1B and Figure 3B and Supplementary Table S4 ). A synergistic effect of Riluzole, SKA-31 and E4031 was also observed with Oxaliplatin (Table 1B and Supplementary Table S6 ), which was weakly efficacious when tested alone on HCT-116 cells ( Table 1A) . All drugs increased the pro-apoptotic effect of Cisplatin in HCT-116 cells (Table 1B) , while the effects of the combination treatments on cell cycle were less homogeneous ( Supplementary Table S7 ). TRAM-34, which was antagonistic in HCT-116 cells, only slightly increased the percentage of cells in early apoptosis and the percentage of cells in G2/M ( Supplementary Table S7 ). In HCT-8 cells, all the K þ channel modulators were antagonistic to Cisplatin ( Supplementary Table  S5 ) and decreased apoptosis ( Supplementary Table S8 ). Next, we studied the signalling pathways underlying such effects, focussing on Caspase 3 activation and the inhibition of antiapoptotic molecules, such as ERK1/2 and Akt (Wong, 2011) . Cisplatin activated Caspase 3, with no or only a small effect on ERK and Akt phosphorylation. The combination of Cisplatin with K Ca 3.1 activators (Riluzole or SKA-31) further activated Caspase 3 and reduced Akt phosphorylation, without affecting the ERK1/2 pathway. Cisplatin and TRAM-34 decreased ERK1/2 phosphorylation and increased Caspase 3 activation but did not affect Akt phosphorylation. The combination of Cisplatin with E4031 strongly decreased ERK1/2 and Akt phosphorylation and activated Caspase 3 ( Figure 3C ). Overall, the synergistic pro-apoptotic effects of Cisplatin with Riluzole, SKA-31 and E4031 were mediated by both the Akt and Caspase 3 pathways. E4031 also modulated the MAPK pathway. Cisplatin and TRAM-34 were antagonistic because of a lack of convergence on the Akt pathway, which could impair completing the apoptotic process (see the relatively low percentage of cells in late apoptosis observed in cells treated with Cisplatin and TRAM-34 in Table 1B) .
Riluzole, SKA-31 and E4031 had a synergic effect with Cisplatin also on the inhibition of HCT-116 cell proliferation. This effect was particularly evident with low Cisplatin concentrations, and the strongest effect was obtained with E4031 ( Figure 3D ).
We then studied whether the antiproliferative effects and the synergy with Cisplatin of drugs that activate K Ca 3.1 (Riluzole, SKA-31) or inhibit K v 11.1 (E4031) depended on their effects on either K Ca 3.1 or K v 11.1 currents. Hence the drugs were tested in K v 11.1-and K Ca 3.1-silenced HCT-116 cells. The silencing of K v 11.1 and K Ca 3.1 by specific siRNAs is shown in Supplementary  Figure S4 . Silencing K v 11.1 potentiated the Cisplatin effects in combination with Riluzole or SKA-31 while it abrogated the effects of E4031 ( Figure 3E, left panel) . Conversely, silencing K Ca 3.1 reversed the effects of both Riluzole and SKA-31 ( Figure 3E , right panel). We conclude that specific activation of K Ca 3.1 and/or inhibition of K v 11.1 underlie the synergistic antiproliferative effects of Riluzole, SKA-31 or E4031 in combination with Cisplatin.
K þ channel modulators increase Cisplatin uptake in CRC cells. We next tested whether Riluzole, SKA-31 or E4031 affected Cisplatin uptake, measured as intracellular accumulation of Platinum (Pt), in HCT-116 cells. We first analysed the role of Cu transporters, determining the dose dependence of Cisplatin accumulation in the absence or presence of 1 mM CuSO 4 to inhibit Cu transporters (Matsumoto et al, 2007) . Unexpectedly, CuSO 4 had no effect. Hence, Cu transporters do not have a significant role in the intracellular accumulation of Cisplatin in these cells. The same experiment was performed in the presence of 25 mM TRAM-34, a dose that fully inhibits K Ca 3.1, without affecting cell viability after a 3 h incubation (Supplementary Figure S5A ). Blocking K Ca 3.1 channels reduced Cisplatin uptake ( Figure 4A ). This result was confirmed by incubating the cells for 3 h with the IC 50 dose (22 mM) of Cisplatin ( Figure 4B ). Hence, the activity of K Ca 3.1 channels determines or at least contributes to the uptake of Cisplatin in HCT-116 cells. Consistently, Riluzole increased Cisplatin accumulation ( Figure 4B ). A similar mechanism was observed for Oxaliplatin uptake ( Figure 4B ). Recalling the opposing effects of TRAM-34 (depolarisation) and Riluzole (hyperpolarisation) on V REST of HCT-116 cells (Figure 2) , we also evaluated the effect of membrane depolarisation on Cisplatin uptake. Cells were depolarised by exposure to a high K þ medium (either 40 or 108 mM), which increased Pt uptake. The effect depended on K Ca 3.1 activity (as it was reduced by TRAM-34) but not on Ca 2 þ influx through voltage-gated Ca 2 þ channels (as 200 mM CdCl 2 had no effect; Becchetti et al, 1992) . Cisplatin uptake was then determined after longer (24 h) treatment with Cisplatin (at the IC 50 dose), alone or in combination with our K þ current modulators. Riluzole, SKA-31 and E4031 increased, while TRAM-34 decreased, Cisplatin accumulation ( Figure 4C ). TRAM-34 inhibited the potentiation of Cisplatin uptake induced by SKA-31 or Riluzole, while it did not affect the potentiation by E4031. Finally, the combination of SKA-31 and E4031 induced the largest increase in Cisplatin uptake ( Figure 4C) . These data suggest that Cisplatin uptake in HCT-116 cells is facilitated by K Ca 3.1 channels, being increased by their activation and reduced by their inhibition.
To determine why K v 11.1 inhibition alone increased Cisplatin uptake, we examined whether K v 11.1 activity was related to K Ca 3.1 expression and/or activity. K Ca 3.1 channel activity ( Figure 4D ) and expression ( Figure 4E) were analysed in HCT-116 cells treated for 24 h with E4031. Treatment with TRAM-34 was included as a control. E4031 augmented both K Ca 3.1 current amplitude ( Figure 4D ) and membrane expression ( Figure 4E ), both when it was applied alone and in the presence of Cisplatin ( Figure 4E ). TRAM-34 blocked K Ca 3.1 activity, as expected ( Figure 4D ), but scarcely affected its surface expression ( Figure 4E ). Neither TRAM-34, nor E4031 altered K v 11.1 expression (Supplementary Figure  S5B) . Hence, in HCT-116 cells, inhibition of K v 11.1 currents was compensated by the increased expression of K Ca 3.1. TRAM-34 (25 mM) did not completely block K Ca 3.1 currents in E4031-treated cells ( Figure 4D ), as it did not completely block Cisplatin uptake in E4031-treated cells ( Figure 4C ). Overall, we attribute the increase in Cisplatin uptake in the presence of K v 11.1 inhibitors to the upregulation of K Ca 3.1 currents less sensitive to TRAM-34 inhibition, possibly a splice variant or a posttranslationally modified form (see Discussion section).
K þ channel modulators overcome Cisplatin resistance in vivo. We next hypothesised that combining a K Ca 3.1 activator and a K v 11.1 inhibitor could potentiate the effect of low doses of Cisplatin (1 mM). Using Cisplatin in the presence of SKA-31, or E4031, or a compound with both effects (Riluzole) reduced cell viability to a greater extent than observed with each compound alone ( Figure 5A ). The most effective combination was Cisplatin þ Riluzole þ E4031 (see also the CI in Table 1B ; note that both Riluzole and E4031 are K v 11.1 inhibitors, and their effects are likely to be additive, Figure 2C ).
Finally, we tested whether the above synergistic effects also occurred in a preclinical in vivo model of chemoresistance. HCT-116 cells were xenografted subcutaneously into immunodeficient nude mice. Both Cisplatin (0.35 mg kg À 1 , twice a week) and Riluzole (10 mg kg À 1 , daily) reduced HCT-116 tumour growth, when added as single agents ( Figure 5B and inset) . The inhibitory effects of E4031 on tumour growth in the same mouse model have already been reported (Crociani et al, 2013 ). Moreover, we tested Riluzole and E4031 in a mouse model we have developed to mimic chemoresistance (see Supplementary Materials and Methods). To this purpose, xenografted mice were first treated with Cisplatin IC 50 values were determined after 24 h of treatment by the Trypan Blue exclusion test, using the Origin Software. Apoptosis and cell cycle distributions were evaluated by treating the cells with the drug concentrations indicated in the third column for 24 h. The percentage of cells in early (Annexin þ /PI À cells) and late apoptosis (Annexin þ /PI þ cells) was determined by Annexin/PI assay as detailed in the Materials and Methods section. Cell cycle distribution was assessed by flow cytometry after staining the cells with propidium iodide (PI) and is indicated as the percentage of cells in the different cell cycle phases. Data are means ± s.e.m. of three independent experiments, each carried out in triplicate. For statistical analysis, Student's t-test was applied.
(0.35 mg kg À 1 , twice a week) for 1 week (Phase 1) and then with a 10 times lower dose (0.035 mg kg À 1 ) for a further 2 weeks (Phase 2). During Phase 2, Riluzole þ E4031 were included in the treatment schedule (see the scheme in Figure 5C ). Tumours decreased their growth by Cisplatin treatment during Phase 1 but recovered their growth during Cisplatin treatment in Phase 2, with approximately the same rate as displayed by the controls. In contrast, when both Riluzole and E4031 were included in the treatment schedule of Phase 2, both the growth rate and the final volume of tumours were significantly reduced ( Figure 5C ). Consistently, such treatment induced a strong decrease of ERK1/ 2 and Akt phosphorylation and an increased activation of caspase 3 ( Figure 5D ).
DISCUSSION
In search of novel strategies to overcome Cisplatin resistance in CRC, we tested the effects of K þ channel modulators in combination with Cisplatin. We show that compounds that activate K Ca 3.1 (SKA-31) or inhibit K v 11.1 (E4031) or have both effects (Riluzole) promote Cisplatin uptake and enhance apoptosis of Cisplatin-resistant cells both in vitro and in a preclinical mouse model. Our results highlight the translational potential of using K þ channel modulators to overcome Cisplatin resistance in CRC. Among the different K þ channel-encoding gene tested, Cisplatin-resistant (HCT-116) cells exhibited higher functional expression of K Ca 3.1 and K v 11.1 (hERG1, KCNH2) channels, compared with Cisplatin-sensitive HCT-8 cells. Moreover, the two channels are functionally related in these cells: (1) they set V REST in HCT-116 cells to more hyperpolarised ( À 38.5 vs À 13 mV) values compared with HCT-8 cells; and (2) their expression is coordinated in HCT-116 cells, one compensating for the other. In fact, prolonged (24 h) inhibition of K v 11.1 currents leads to upregulation of functional K Ca 3.1 channels ( Figure 4D and E). As all described CRC cell lines express K v 11.1 (D'Amico et al, 2013) and K Ca 3.1 inhibition has no effect on K v 11.1 (Supplementary Figure S5B ), we hypothesise that K v 11.1 drives the expression of the other K þ channel. The coordinated and balanced expression of the two K þ channels has two consequences in HCT-116 cells: (A) blocking K v 11.1 increases the uptake of Cisplatin, which relies on the activity of K Ca 3.1 channels, and (B) the concomitant activation of K Ca 3.1 and inhibition of K v 11.1 potentiates the pro-apoptotic activity of Cisplatin. Cisplatin uptake into HCT-116 cells is reduced by TRAM-34, a specific K Ca 3.1 blocker, and it is increased by SKA-31 and Riluzole, which activate K Ca 3.1. These results suggest a requirement for K Ca 3.1 in Cisplatin uptake. Blocking K v 11.1 (hERG1) with E4031 also enhances Cisplatin uptake, an effect that can be explained by E4031-induced upregulation of K Ca 3.1 (Table 2) . Notably, the K Ca 3.1 upregulation triggered by E4031 is not completely blocked by TRAM-34. This decreased TRAM-34 sensitivity may be due to upregulation of a posttranslationally modified K Ca 3.1 protein (see K Ca 3.1 band of higher molecular weight, that is, more glycosylated, in Figure 4D ) or a K Ca 3.1 splice variant with reduced TRAM-34 sensitivity as reported in the rat colon (Barmeyer et al, 2010) . This could also explain why increased Cisplatin uptake in cells treated with E4031 was not completely reversed by TRAM-34 addition.
Moreover, the inhibitory effect of TRAM-34 was not related to its depolarising action. In fact, exposing the cells to high (25) 3.36 ± 0.34 A ND ND Oxaliplatin (60) þ E4031 (7) 0.83 ± 0.01 S ND ND Abbreviation: ND ¼ not determined. CI41, antagonism (A); CI ¼ 1, additivity (Ad); CIo1, synergy (S). HCT-116 cells were exposed to Cisplatin or Oxaliplatin in combination with Riluzole, SKA-31, TRAM-34 and E4031 for 24 h as described in Pillozzi et al, 2011 . All the drugs were used at drug concentrations indicated in the first column. Data are means ± s.e.m. of three independent experiments, each carried out in triplicate. CI values were calculated using the Calcusyn software Version 2 (Biosoft). For statistical analysis, Student's t-test was applied. extracellular K þ concentrations (40 and 108 mM, which set V REST at À 10 and 0 mV, respectively) increased Cisplatin uptake. One possibility to explain this effect is that K Ca 3.1 modulates VRAC, which was found to mediate Cisplatin uptake (Jentsch et al, 2016) . HCT-116 cells do show a substantial expression of LRRC8D, the main molecular component of VRAC implicated in cell volume regulation (Planells-Cases et al, 2015; Syeda et al, 2016) . In this case, Cisplatin uptake through VRAC would be modulated by the activity of K Ca 3.1. Another possibility is that the depolarisation caused by high extracellular K þ also decreases the driving force for Cl À , leading to a smaller ratio between the outward and the inward flux. The consequent relative increase of inward Clflux would facilitate Pt entry, compared with the basal conditions. In Cisplatin-resistant CRC cells, K Ca 3.1 activators (SKA-31), K v 11.1 inhibitors (E4031) and compounds with both activities (Riluzole) displayed a synergistic action with Cisplatin. In fact, they restored the pro-apoptotic and cytotoxic effects of Cisplatin, even when the latter was tested at very low doses. The effect of E4031 in CRC cells is the opposite of that observed after silencing K v 11.1/ hERG1 in gastric cancer cells (Zhang et al, 2012) , suggesting that different channel-dependent mechanisms are operant in CRC cells. The effects of our K þ channel-modulating drugs on apoptosis and cell cycle phases were generally stronger in Cisplatin-resistant cells. Moreover, in these cells, only K Ca 3.1 activators and K v 11.1 inhibitors were synergistic with Cisplatin, thus increasing the percentage of apoptotic cells, and affecting the relative intracellular signalling pathways (Table 2) .
Although we studied mainly Cisplatin, the effects we observed were also evident with Oxaliplatin, stressing the translatability of our data. Overall, we believe that the results discussed herein may be of relevance for overcoming chemoresistance to Pt-based drugs, one of the major challenges in cancer treatment (Kartalou and Essigmann, 2001; Siddik, 2003; Wang and Lippard, 2005) .
In our CRC model, HCT-116 cells, although expressing K Ca 3.1, have a low Cisplatin uptake because the activity of K Ca 3.1 is kept low by the concomitant K v 11.1 activity. The combination of K Ca 3.1 activation with K v 11.1 inhibition, improving Cisplatin uptake, allows also low doses of the drug to trigger apoptosis and reduce HCT-116 cell growth. This interpretation explains why a K Ca 3.1 activator and a K v 11.1 inhibitor can be combined to trigger a cooperative effect with Cisplatin. The best combination includes Riluzole, which has a mild K v 11.1 inhibitory activity, besides activating K Ca 3.1. In the present paper, we provide evidence that such cooperation occurs both in vitro and in vivo and in preclinical models (subcutaneous xenografts of HCT-116 cells into immunodeficient mice) and contributes to overcome Cisplatin resistance.
In these models, we tested Riluzole and E4031 applying dosages and routes of administrations already used and proven to be efficacious (Yip et al, 2009; Crociani et al, 2013; Speyer et al, 2016) . We showed the capacity of the combination of the two drugs to improve Cisplatin antineoplastic effects. In particular ( Figure 5C ), we mimicked in mice the onset of chemoresistance in mice, treating the xenografted animals with full Cisplatin doses first and then with very low doses. In the latter case, tumours started to grow again, except when Riluzole and E4031 were included in the chemotherapeutic regimen. It is worth noting that the mouse model of chemoresistance we produced allowed us to unravel the effects of the combination, which was however masked by the intense effect of Cisplatin at full doses.
During CRC adjuvant therapy, the combination of Cisplatin (Oxaliplatin) with drugs that activate K Ca 3.1 and inhibit K v 11.1, such as Riluzole, may improve Cisplatin (Oxaliplatin) efficacy and overcome resistance in the clinical setting. Such combination would represent an example of personalised medicine in those patients who co-express K Ca 3.1 and K v 11.1 (Muratori et al., 2016) . Importantly, Riluzole is already in clinical use for the treatment of amyotrophic lateral sclerosis and is being investigated for the treatment of solid tumours in several clinical trials (https:// clinicaltrials.gov/, NCT00903214 and NCT0086684). Of interest, Riluzole, showed preliminary benefit in a Phase 0 trial in patients with advanced melanoma and is currently in Phase 2 clinical trials (NCT0086684; Yip et al, 2009 ) and in Phase 1 for breast cancer (NCT00903214). Besides its effect on K Ca 3.1 and K v 11.1 in CRC cells, Riluzole may also enhance antitumour T-cell activity by overcoming the recently described ionic immune checkpoint (Eil et al, 2016) . A combination of Riluzole with Cisplatin may show clinical benefit.
